ERISPharmaceuticals
Eris Lifesciences Ltd — PE Ratio & Valuation Analysis
₹1297.20
+2.05%
Current P/E51.82xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E40.0x29.5% above avg
⚠️
63.1% Premium to Industry
ERIS P/E 51.82x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹25.81 | ₹1506 | 58.3x |
| 2024 | ₹28.79 | ₹1374 | 47.7x |
| 2023 | ₹28.07 | ₹910 | 32.4x |
| 2022 | ₹29.88 | ₹647 | 21.7x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Eris Lifesciences Ltd Valuation
Eris Lifesciences Ltd (ERIS) currently trades at 51.82x earnings. The Pharmaceuticals sector average PE is 31.77x. ERIS commands a premium, reflecting high growth expectations. Historically, ERIS has traded at an average PE of 40.0x — it is currently above that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
12.88%
Dividend Yield
0.46%
More on Eris Lifesciences Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.